Clinical Trial Update: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for AZD2936, a bispecific anti-TIGIT/anti-PD-1 antibody, in participants with advanced or metastatic non-small cell lung cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD2936 (AZD2936)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING